Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Gains from Investment Securities (2023 - 2025)

Mangoceuticals' Gains from Investment Securities history spans 3 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 14900.38% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, up 14900.38%, while the annual FY2024 figure was $156666.0, 11.32% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $2.0 million at Mangoceuticals, up from $156666.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.4 million in Q1 2024 and bottomed at $13333.0 in Q3 2024.
  • The 3-year median for Gains from Investment Securities is $166666.0 (2023), against an average of $888666.4.
  • The largest YoY upside for Gains from Investment Securities was 14900.38% in 2025 against a maximum downside of 93.38% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at $176666.0 in 2023, then fell by 11.32% to $156666.0 in 2024, then soared by 1176.6% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Gains from Investment Securities are $2.0 million (Q3 2025), $156666.0 (Q2 2025), and $156666.0 (Q1 2025).